Candidate drug EDP-305 reduced fibrosis progression and improved non-alcoholic fatty liver disease (NAFLD) and primary biliary cholangitis (PBC) disease settings in several preclinical animal models, says…
Cholangitis
Recent Posts
- Alagille syndrome linked to glaucoma risk in study of 2 brothers
- Health Canada expands Maviret use for acute hepatitis C in children, adults
- New study finds higher cancer risk in PSC with advanced dysplasia
- Could GLP-1 medications be the future of fatty liver disease treatment?
- Plant compounds offer new clues about gut bacteria and cholestasis